At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 26 enrolled
Drug / intervention
Astaxanthin +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Astaxanthin Supplementation Preserves Cognitive Markers of Executive Function Following Mental Fatigue in Females
In Brief
A Phase 4 clinical trial evaluating Astaxanthin and Placebo for Mental Fatigue. Completed, enrolled 26 participants across 1 site.
Detailed Summary
The purpose of this study is to examine the protentional that the antioxidant Astaxanthin has on mitigating cognitive decline following mental fatigue.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMental Fatigue
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20252026
First PostedJun 2024
Enrollment StartAug 2024
Primary CompletionNov 2024
Study CompletionDec 2024
TodayJul 2026
First PostedJun 14, 2024
Enrollment StartAug 1, 2024
Primary CompletionNov 1, 2024
Study CompletionDec 14, 2024
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 2.1 years ago
Interventions
Astaxanthindietary
Manufactured by AstaReal Inc
Placebodietary
Manufactured by AstaReal Inc